MDT

96.83

-2.02%↓

A

139.62

-3.71%↓

VEEV

222.3

+1.47%↑

HQY

85.02

-2.1%↓

NEOG

9.24

-2.22%↓

MDT

96.83

-2.02%↓

A

139.62

-3.71%↓

VEEV

222.3

+1.47%↑

HQY

85.02

-2.1%↓

NEOG

9.24

-2.22%↓

MDT

96.83

-2.02%↓

A

139.62

-3.71%↓

VEEV

222.3

+1.47%↑

HQY

85.02

-2.1%↓

NEOG

9.24

-2.22%↓

MDT

96.83

-2.02%↓

A

139.62

-3.71%↓

VEEV

222.3

+1.47%↑

HQY

85.02

-2.1%↓

NEOG

9.24

-2.22%↓

MDT

96.83

-2.02%↓

A

139.62

-3.71%↓

VEEV

222.3

+1.47%↑

HQY

85.02

-2.1%↓

NEOG

9.24

-2.22%↓

Search

Boston Scientific Corp.

Closed

SectorHealthcare

88.13 -2.07

Overview

Share price change

24h

Current

Min

88.09

Max

88.48

Key metrics

By Trading Economics

Income

1.4B

2.2B

Sales

4M

5.1B

P/E

Sector Avg

51.187

90.831

EPS

0.75

Profit margin

43.87

Employees

53,000

EBITDA

-341M

1B

Recommendations

By TipRanks

Recommendations

Strong Buy

12 Months Forecast

+42.82% upside

Dividends

By Dow Jones

Next Earnings

5 Feb 2026

Market Stats

By TradingEconomics

Market Cap

-7.1B

142B

Previous open

90.2

Previous close

88.13

News Sentiment

By Acuity

61%

39%

298 / 361 Healthcare

Technical Score

By Trading Central

Confidence

Bullish Evidence

Boston Scientific Corp. Chart

Past performance is not a reliable indicator of future results.

Related News

15 Jan 2026, 13:29 UTC

Acquisitions, Mergers, Takeovers

Boston Scientific to Buy Penumbra for $15 Billion in Cash, Stock -- 2nd Update

15 Jan 2026, 12:35 UTC

Acquisitions, Mergers, Takeovers

Boston Scientific to Buy Penumbra for $15 Billion in Cash, Stock -- Update

15 Jan 2026, 12:29 UTC

Acquisitions, Mergers, Takeovers

Boston Scientific to Buy Penumbra for $15 Billion in Cash, Stock

22 Oct 2025, 11:00 UTC

Earnings

Boston Scientific Raises Outlook on Continued Cardiovascular Growth

15 Jan 2026, 14:37 UTC

Hot Stocks

Stocks to Watch Thursday: Goldman Sachs, Boston Scientific, BlackRock -- WSJ

15 Jan 2026, 13:45 UTC

Acquisitions, Mergers, Takeovers

Penumbra Stock Jumps. It's Being Bought by Boston Scientific for $14.5 Billion. -- Barrons.com

15 Jan 2026, 12:04 UTC

Acquisitions, Mergers, Takeovers

Boston Scientific: Penumbra Shareholders Can Elect to Receive Cash or Stock >BSX PEN

15 Jan 2026, 12:03 UTC

Acquisitions, Mergers, Takeovers

Boston Scientific: Acquisition to Expand Cardiovascular Portfolio >BSX PEN

15 Jan 2026, 12:01 UTC

Acquisitions, Mergers, Takeovers

Boston Scientific: Penumbra Deal Carriers an Enterprise Value of About $14.5 Billion >BSX

15 Jan 2026, 12:00 UTC

Acquisitions, Mergers, Takeovers

Boston Scientific to Buy Penumbra for $374/Share >BSX PEN

15 Jan 2026, 12:00 UTC

Acquisitions, Mergers, Takeovers

Boston Scientific Announces Agreement To Acquire Penumbra, Inc. >BSX PEN

12 Jan 2026, 12:04 UTC

Acquisitions, Mergers, Takeovers

Boston Scientific Sees Immaterial Impact to 2026 Adjusted EPS >BSX

12 Jan 2026, 12:04 UTC

Acquisitions, Mergers, Takeovers

Boston Scientific: Specific Terms of Valencia Transaction Not Disclosed >BSX

12 Jan 2026, 12:03 UTC

Acquisitions, Mergers, Takeovers

Boston Scientific: Valencia Focused on Development of Solutions to Treat Bladder Dysfunction >BSX

12 Jan 2026, 12:00 UTC

Acquisitions, Mergers, Takeovers

Boston Scientific Announces Agreement To Acquire Valencia Technologies Corporation >BSX

18 Nov 2025, 17:06 UTC

Earnings

Medtronic Stock Rises After Earnings. What Caught Investors' Attention. -- Barrons.com

18 Nov 2025, 12:01 UTC

Earnings

Medtronic Stock Rises After Earnings. What Caught Investors' Attention. -- Barrons.com

30 Oct 2025, 12:38 UTC

Earnings

Looking to Diversify Out of the AI Trade? Buy Boston Scientific Stock. -- Barrons.com

30 Oct 2025, 12:01 UTC

Earnings

Looking to Diversify Out of the AI Trade? Buy Boston Scientific Stock. -- Barrons.com

22 Oct 2025, 10:32 UTC

Earnings

Boston Scientific Sees 4Q Organic Sales Up 11%-13% >BSX

22 Oct 2025, 10:32 UTC

Earnings

Boston Scientific Sees 4Q Sales Up 14.5-16.5% >BSX

22 Oct 2025, 10:31 UTC

Earnings

Boston Scientific Sees 2025 Organic Sales Up About 15.5% >BSX

22 Oct 2025, 10:31 UTC

Earnings

Boston Scientific Sees 2025 Sales Up About 20% >BSX

22 Oct 2025, 10:30 UTC

Earnings

Boston Scientific Sees FY Adj EPS $3.02-Adj EPS $3.04 >BSX

22 Oct 2025, 10:30 UTC

Earnings

Boston Scientific 3Q Organic Sales Up 15.3% >BSX

22 Oct 2025, 10:30 UTC

Earnings

Boston Scientific 3Q Adj EPS 75c >BSX

22 Oct 2025, 10:30 UTC

Earnings

Boston Scientific Sees FY EPS $1.97-EPS $2.01 >BSX

22 Oct 2025, 10:30 UTC

Earnings

Boston Scientific Sees 4Q EPS 48c-EPS 52c >BSX

22 Oct 2025, 10:30 UTC

Earnings

Boston Scientific 3Q Sales $5.07B >BSX

22 Oct 2025, 10:30 UTC

Earnings

Boston Scientific 3Q EPS 51c >BSX

Peer Comparison

Price change

Boston Scientific Corp. Forecast

Price Target

By TipRanks

42.82% upside

12 Months Forecast

Average 125.78 USD  42.82%

High 140 USD

Low 112 USD

Based on 20 Wall Street analysts offering 12 month price targets forBoston Scientific Corp. - Dist in the last 3 months.

Rating Consensus

By TipRanks

Strong Buy

20 ratings

20

Buy

0

Hold

0

Sell

Technical Score

By Trading Central

102.95 / 104.93Support & Resistance

Short Term

Bullish Evidence

Intermediate Term

Weak Bearish Evidence

Long Term

No Evidence

Sentiment

By Acuity

298 / 361 Healthcare

News Sentiment

Bearish Evidence

Volatility

Below average

News Volume (RCV)

Above average

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

$

About Boston Scientific Corp.

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system. It also provides technologies for diagnosing and treating coronary artery disease and aortic valve conditions; WATCHMAN FLX, a Left Atrial Appendage Closure Device; and implantable devices that monitor the heart and deliver electricity to treat cardiac abnormalities, such as cardioverter and cardiac resynchronization therapy defibrillators, MRI S-ICD systems, cardiac resynchronization therapy pacemakers, quadripolar LV leads, ICD leads, pacing leads, remote patient management systems, insertable cardiac monitor systems, and remote cardiac monitoring systems. In addition, the company offers diagnosis and treatment of rate and rhythm disorders of the heart; peripheral arterial and venous diseases; and products to diagnose, treat and ease forms of cancer. The company was incorporated in 1979 and is headquartered in Marlborough, Massachusetts.
help-icon Live chat